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sel, Basel, Switzerland. This study aimed to assess cost-effectiveness of N-terminal pro-B-type natriuretic peptide (NT-proBNP)-guided versus
symptom-guided therapy in heart failure (HF) patients 60 years old.Background Cost-effectiveness of NT-proBNP guidance in HF patients is unclear. It may create additional costs with uncertain
benefits.Methods In the TIME-CHF (Trial of Intensified versus Standard Medical Therapy in Elderly Patients with Congestive Heart
Failure), patients with left ventricular ejection fraction (LVEF) of 45% were randomized to receive intensified
NT-proBNP-guided therapy or standard, symptom-guided therapy. For cost-effectiveness analysis, 467 (94%) patients
(age 76  7 years, 66% male) were eligible. Incremental cost-effectiveness was calculated as incremental costs per
gained life-year and quality-adjusted life-year (QALY) within the 18-month trial period, as defined per protocol.Results NT-proBNP-guided therapy was dominant (i.e., more effective and less costly) over symptom-guided therapy, saving
$2,979 USD (2.5 to 97.5% confidence interval [CI]: $8,758 to $3,265) per patient, with incremental effectiveness
of þ0.07 life-years and þ0.05 QALYs. The probability of NT-proBNP-guided therapy being dominant was 80%, and
the probability of saving 1 life-year or QALY at a cost of $50,000 was 97% and 93%, respectively. Exclusion of
residence costs resulted in an incremental cost-effectiveness ratio (ICER) of $5,870 per life-year gained. Cost-
effectiveness of NT-proBNP-guided therapy was most pronounced in patients <75 years old and in those with
<2 significant comorbidities, being dominant in all sensitivity analyses. In the worst-case scenario (excluding
residence costs in those with 2 comorbidities), the ICER was $11,935 per life-year gained.Conclusions NT-proBNP-guided therapy has a high probability of being cost effective in HF patients with reduced LVEF,
particularly in patients age 60 to 75 years or with less than 2 comorbidities. (Trial of Intensified versus standard
Medical therapy in Elderly patients with Congestive Heart Failure [TIME-CHF]; ISRCTN43596477) (J Am Coll
Cardiol HF 2013;1:64–71) ª 2013 by the American College of Cardiology FoundationHeart failure (HF) is a large-scale health care problem in
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HF = heart failure
ICD = implantable
cardioverter-defibrillator
ICER = incremental cost-
effectiveness ratio
LVEF = left ventricular
ejection fraction




SF-12 = short form-12
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65cardioverter-defibrillators [ICDs] and cardiac resynchroni-
zation therapy [CRT]) (3,4) may increase the need for
resources devoted to HF treatment even further. With
growing demands on limited health care budgets, optimal
resource allocation in HF patients is essential. Thus, the
adoption of new medical treatments depends increasingly on
evidence of cost-effectiveness (5). HF therapy guided by
natriuretic peptides, mainly N-terminal pro-B-type natri-
uretic peptides (NT-proBNP), has been shown to reduce all-
cause mortality in patients with chronic HF compared with
conventional, symptom-guided clinical care (6,7), especially
in patients< 75 years old (8,9), but results were not uniform.
It was previously suggested that NT-proBNP-guided therapy
might be cost effective, but true cost-effectiveness including
sensitivity analyses was not calculated in those studies (10,11).
Because NT-proBNP therapy guidance in HF is believed to
create additional costs with uncertain benefits, it is not yet
recommended. Therefore, we studied cost-effectiveness of the
largest randomized trial to date that compared intensified NT-
proBNP-guided therapy with standard, symptom-guided
therapy. This analysis was predefined by protocol of the
TIME-CHF (Trial of Intensified versus Standard Medical
Therapy inElderly patientswithChronicHeartFailure) (8,12).Methods
Study design and patients. Study design of the TIME-
CHF randomized, multicenter trial was published in detail
previously (8,12). Briefly, 499 patients age 60 years (no
upper age limit), with New York Heart Association (NYHA)
functional class II HF, left ventricular ejection fraction
(LVEF) of 45%, and elevated NT-proBNP levels were
randomized to receive intensified NT-proBNP-guided
therapy or standard, symptom-guided therapy. Guideline-
recommended HF therapy (13) was intensified based on
predefined escalation rules (12) guided by symptoms alone
(symptom-guided group) or additionally by NT-proBNP
levels (NT-proBNP-guided group). Patients were followed
for 18 months.
Patients who withdrew consent before 90 days of follow-up
(n¼ 30) or who were lost to follow-up (n¼ 2) were excluded
from cost-effectiveness evaluation. Patients without any valid
short form-12 (SF-12) questionnaire (n ¼ 19) were removed
from the quality-adjusted life-year (QALY) analysis (Online
Fig. 1). Patients with missing data in questionnaires (n ¼
172) or cost data (n ¼ 29) were included on an intention-
to-treat basis, and missing data were imputed, using the last
telephone contact as censoring date.
The study obtained primary ethics approval from the
Ethics Committees of the University Hospital Basel and
complies with World Medical Association’s 2008 Declara-
tion of Helsinki. All participants gave informed consent
before taking part in the study.
Outcome measures: effectiveness estimates. Effectiveness
was expressed as life-years and QALYs gained. Life-years are
based on overall survival during the 18-month study period.QALYswere calculated using SF-
6D preference weights from the
SF-12 questionnaire at baseline,
12, and 18 months (14).
Outcome measures: resource
volumes and unit costs. Re-
source use was collected on a
patient level at every study visit,
as defined per protocol (8,12).
A bottom-up cost accounting
approach was used, wherein the
sum of resources times their unit
price yielded the total costs. Unit
prices are summarized in Online
Tables I to III (15,16). Costs for
absence of paid work were not
taken into account (most were
>65 years old). Costs were
determined from the perspective
of third party payers. Costs were collected in Swiss currency,
2006 price level, and converted to US dollars, using the
January 1, 2006 conversion rate (where $1 US ¼ 1.28 Swiss
francs). Costs were not discounted due to the limited
follow-up of 18 months.
Cost-effectiveness outcomes. The primary outcome mea-
sure was incremental costs per life-year gained; the secondary
outcome measure, was incremental costs per QALY gained.
These were expressed as incremental cost-effectiveness ratios
(ICERs): where D costs (between groups)/D effectiveness
(between groups). The uncertainty surrounding the ICER is
presented in cost-effectiveness planes and cost-effectiveness
acceptability curves (CEACs) (17).
Statistical analysis. Baseline results are presented asmean
SD,median interquartile ranges (IQR), or as frequencies with
percentages. Between-group comparisons were performed
using the t-test, the Mann-Whitney U test, or the Pearson
chi-square test, as appropriate. Resource use data are pre-
sented as means with standard error of the mean despite non-
normal distribution because they better represent per patient
data than median values and were compared using nonpara-
metric testing. Costs, life-years, and QALYs are presented as
means with 2.5 to 97.5% bootstrapped intervals. Between-
group comparisons of costs were performed using the boot-
strap t-test (5). Between-group comparisons of effects were
performed using nonparametric testing. Multiple imputation
was performed using predictive mean matching, incorpo-
rating random variation, and including relevant variables
for estimation, with 5 repetitions. A joint comparison of
costs and effects was performed by nonparametric boot-
strapping with 1,000 resamples (18). Subgroup analyses were
performed according to age (pre-specified) and to number
of comorbidities and presence of kidney disease (not pre-
specified) (12). Sensitivity analyses were conducted to account
for uncertainties that could influence cost-effectiveness
outcomes and consisted of 1) varying the price of NT-
proBNP measurement by 50%; 2) varying price levels of
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66inpatient costs in steps of 10%, up to 30%; 3) excluding
residence costs; 4) excluding subjects with imputed cost data;
5) including all patients on an intention-to-treat basis and
treating those who were lost or withdrew as dead; and 6)
applying a method for CEACs that does not accept losing
effectiveness (19).
Sample size was based on the primary outcome measure
of the trial (i.e., hospital-free survival). To show cost-
effectiveness at a threshold of $50,000, a power of 80%,
and a significance level of 5%, the required sample size
would be n ¼ 445 per treatment arm (17). A w-sided p value
of 0.05 was considered statistically significant. Analyses were
done using SPSS version 18.0 software (SPSS Inc., Chicago,
Illinois).Results
Patient characteristics. Patients were 76  7 years of age,
two-thirds weremale, meanLVEFwas 30 8%, and ischemia
was the primary cause of HF in most patients. At baseline,
characteristics were matched between treatment groups
(Table 1). Patients in the older age group were characterized by
more severe symptoms, higher NT-proBNP levels, more
comorbidities, lower usage of HF medication, and higher
LVEFthan the younger age group (Table 1).Patientswhowere
excluded from this analysis (n¼ 32) differed significantly from
the included patients regarding age, clinical presentation,
medical history, and medication use (Online Appendix).
Effectiveness estimates. At the 18-month follow-up visit,
effect in terms of life-years was in favor of NT-proBNP-






Age (yrs) 76  8 75  7
Male (%) 146 (64) 164 (69)
NYHA functional class III (%) 166 (73) 174 (73)
CAD cause of HF (%) 138 (61) 128 (54)
Renal failure (%) 123 (54) 132 (55)
Comorbidities 2 (%) 167 (73) 172 (72)
Systolic BP (mm Hg) 118  18 118  18
LVEF (%) 30  11 30  10
NT-proBNP (pg/ml) 4,472 (2,428–7,371) 3,849 (1,944–6,8
RAS blockade (%) 216 (95) 226 (95)
Daily dose (% of target dose) 50 (25–100) 50 (25–100)
Beta-blocker (%) 188 (83) 184 (77)
Daily dose (% of target dose) 25 (12.5–50) 25 (6.25–50)
Spironolactone (%) 94 (41) 97 (41)
Daily dose (mg) 0 (0–25) 0 (0–25)
Loop diuretics (%) 214 (94) 221 (93)
Daily dose (mg furosemide equivalent) 80 (40–100) 60 (40–80)
Residing in nursing facility
or home for the elderly (%)
9 (4) 3 (1)
Values are mean  SD, n (%), or median (interquartile range). Dose of RAS-blockade and beta-blockers
BP ¼ blood pressure; CAD ¼ coronary artery disease; HF ¼ heart failure; LVEF ¼ left ventricular ejection
RAS ¼ renin angiotensin system.NT-proBNP-guided therapy was significantly more effec-
tive than symptom-guided therapy in the younger patients
(Table 2) and in patients with <2 comorbidities (life-years
1.45, 2.5 to 97.5% confidence interval [CI]: 1.39 to 1.49, in
the NT-proBNP-guided group versus 1.34 life-years, 2.5 to
97.5% CI: 1.25 to 1.42, in the symptom-guided group;
p ¼ 0.04). The effect in terms of QALYs showed similar but
nonsignificant results with smaller effect sizes (Table 2).
Resource use and costs. NT-proBNP-guided treatment
introduced more use of HF medication and fewer days in an
home for the elderly than for the symptom-guided group
(Table 3). Use of other categories of resources was similar
between the 2 treatment groups.
A net mean cost reduction of $2,979 (2.5% to 97.5% CI:
$8,758 to $3,265; p¼ 0.24) was achieved with NT-proBNP-
guided therapy compared with symptom-guided therapy
(Table 2), which was caused mainly by a net saving of $3,626
in residence costs (2.5% to 97.5% CI: $7,587 to $208;
p ¼ 0.09). Cost composition into several categories is shown
in Figure 1A, showing that inpatient costs accounted for
most of the total costs (i.e., >50%). Costs of NT-proBNP
measurements added very little to the total costs (i.e., $184,
0.9%). Medical HF therapy costs were significantly higher
in the NT-proBNP-guided group than in the symptom-
guided group ($747 vs. $668, respectively; p ¼ 0.04), but
accounted for <5% of total costs in both treatment groups.
Total costs were significantly higher in the older age group
than in the younger age group ($16,872 vs. $26,692, respec-
tively; increment, $9,819; 2.5 to 97.5%CI: $4,568 to $15,773;
p ¼ 0.001), which was also caused largely by residence costs.






(n ¼ 263) p Value
0.30 69  4 81  4 <0.001
0.33 152 (75) 158 (60) 0.001
1.00 132 (65) 208 (79) 0.001
0.35 99 (49) 167 (64) <0.001
0.85 90 (44) 165 (63) <0.001
0.84 130 (64) 209 (80) <0.001
0.67 116  18 119  18 0.05
0.65 28  10 31  10 0.005
95) 0.09 2,968 (1,655–5,611) 4,948 (2,819–8,286) <0.001
1.00 194 (95) 248 (94) 0.84
0.45 50 (44–100) 50 (25–100) 0.13
0.17 171 (84) 201 (76) 0.05
0.13 25 (12.5–50) 25 (6.25–50) 0.04
0.93 96 (47) 95 (36) 0.02
0.78 0 (0–25) 0 (0–25) 0.03
0.59 185 (91) 250 (95) 0.07
0.09 40 (40–80) 80 (40–120) 0.03
0.08 1 (1) 11 (4) 0.02
is given in % of target dose as stated in the European HF guidelines (13).
fraction; NT-proBNP = N-terminal pro-B-type natriuretic peptide; NYHA = New York Heart Association;
Table 2 Effects and Costs Between Treatment Groups and Age Groups
Parameter* NT-proBNP-Guided Treatment (range) Symptom-Guided Treatment (range) Increment (D) Between Groups (range) p Value
Life-years
Overall 1.33 (1.28 to 1.38) 1.26 (1.20 to 1.32) þ0.07 (0.00 to 0.14) 0.05
Age <75 yrs 1.41 (1.34 to 1.45) 1.28 (1.20 to 1.37) þ0.13 (0.02 to 0.21) 0.03
Age 75 yrs 1.27 (1.20 to 1.34) 1.24 (1.16 to 1.31) þ0.03 (0.08 to 0.14) 0.53
QALYs
Overall 0.91 (0.87 to 0.96) 0.87 (0.82 to 0.92) þ0.05 (0.02 to 0.11) 0.35
Age <75 yrs 1.00 (0.95 to 1.05) 0.91 (0.83 to 0.98) þ0.10 (0.00 to 0.19) 0.12
Age 75 yrs 0.84 (0.78 to 0.90) 0.84 (0.77 to 0.90) 0.005 (0.08 to 0.10) 0.86
Total costs (U.S. $)
Overall 20,949 (17,181 to 25,406) 23,928 (19,272 to 8,633) 2,979 (8,758 to 3,265) 0.24
Age <75 yrs 16,509 (11,689 to 21,949) 17,275 (12,802 to 2,525) 765 (8,072 to 6,952) 0.58
Age 75 yrs 24,547 (18,724 to 30,569) 28,854 (21,760 to 36,443) 4,307 (13,142 to 4,446) 0.33
Costs minus residence (U.S. $)
Overall 16,792 (13,980 to 19,551) 16,364 (13,407 to 9,367) 384 (3,462 to 4,803) 1.0
Age <75 yrs 15,169 (11,177 to 19,782) 14,519 (10,932 to 8,178) 648 (5,113 to 6,221) 0.53
Age 75 yrs 18,107 (14,869 to 21,758) 17,730 (13,721 to 2,057) 378 (5,165 to 5,917) 0.55
*n for overall ¼ 467; 204 for age <75 years; and 263 for age75 years. Costs, life years, and quality-adjusted life-years (QALYs) represent means with bootstrapped confidence intervals of 2.5 to 97.5%. The
p values for life-years and QALYS were derived with the nonparametric Mann-Whitney U test. The p values for costs represent bootstrapped t-test results.
NT-proBNP ¼ N-terminal pro-B-type natriuretic peptide.
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67peak in costs in the first month of follow-up, with relatively
stable costs over the following 17 months.
Cost-effectiveness. NT-proBNP-guided therapy has an
80% chance of being dominant (i.e., more effective and
less costly relative to symptom-guided therapy) (Fig. 2),
whereas the chance of NT-proBNP-guided therapy being
inferior is only 0.1%. The probability of NT-proBNP-
guided therapy being either dominant or having an ICER
below $50,000/life-year gained is 97% (Online Table 4,
Online Fig. 2A).
Age and number of comorbidities considerably reduced






Hospitalization days 15.9 (1.7) 15.6 (1.7)
ICU days 0.80 (0.16) 0.64 (0.12)
No. of procedures 0.16 (0.024) 0.19 (0.025)
No. of CV procedures 0.21 (0.04) 0.27 (0.04)
No. of standard visits 5.6 (0.13) 5.6 (0.12)
No. of extended visits 0.78 (0.065) 0.67 (0.058)
Mean HF medication daily dose
Beta-blocker 27 [14–50] 35 [19–57
RAS blockade 69 [48–100] 85 [54–10
Spironolactone 5 [0–21] 11 [0–24]
Loop diuretics 61 [39–103] 55 [32–10
No. of echocardiography studies 0.097 (0.026) 0.059 (0.016)
No. of chest radiographs 0.11 (0.023) 0.080 (0.019)
No. of NT-proBNP measurements d 3.9 (0.080)
Rehabilitation days 7.7 (1.6) 9.2 (1.6)
Nursing home days 14.6 (4.9) 7.0 (2.9)
Elderly home days 26.6 (7.2) 7.8 (3.7)
Values are mean (standard error of mean) or median [interquartile range]. *Mean dosage over the tota
CV ¼ cardiovascular; HF ¼ heart failure; ICU ¼ intensive care unit; NT-proBNP ¼ N-terminal pro-B-typeffective, whereas the presence of renal disease did not
influence cost-effectiveness (Fig. 2, Online Table 4, Online
Fig. 2A). Nonetheless, the ICER was dominant for all
subgroups, and NT-proBNP-guided therapy had a high
probability (>75%) of being cost effective at threshold of
$50,000 in all subgroups.
After exclusion of residence costs, the ICER for NT-
proBNP-guided therapy was $5,870/life-year saved, and
the probability of cost-effectiveness at $50,000 was 86%.
Excluding residence cost (Online Fig. 2) or defining ICERs
in the less-effective and less costly (i.e., southwestern)




(n ¼ 263) p Value
0.79 13.9 (1.8) 17.2 (1.6) 0.02
0.64 0.81 (0.16) 0.65 (0.13) 0.82
0.39 0.19 (0.03) 0.16 (0.02) 0.52
0.40 0.27 (0.05) 0.22 (0.03) 0.50
0.63 5.8 (0.12) 5.5 (0.12) 0.12
0.31 0.74 (0.07) 0.71 (0.06) 1.0
] 0.30 42 [20–63] 27 [13–50] 0.001
0] 0.007 89 [54–100] 69 [46–100] 0.001
0.04 12 [0–24] 4.4 [0–23] 0.06
2] 0.18 54 [28–96] 61 [37–111] 0.11
0.46 0.12 (0.03) 0.05 (0.01) 0.01
0.33 0.12 (0.03) 0.07 (0.02) 0.09
<0.001 2.1 (0.15) 1.9 (0.13) 0.53
0.09 4.5 (0.82) 11.6 (1.9) 0.003
0.70 3.7 (2.7) 16.0 (4.5) 0.003
0.003 3.9 (2.9) 27.1 (6.7) 0.009
l 18 month study period.
e natriuretic peptide.
Figure 1 Cost Categories and Costs Over Time
Cost categories during 18-month follow-up by treatment group for the overall population, divided by age groups (A), and costs per month by treatment group (B). NT-proBNP ¼
N-terminal pro-brain natriuretic peptide.
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68probability of cost-effectiveness by approximately 30% in
patients 75 years of age and in patients with >2 comor-
bidities. Importantly, results were robust when residence
costs were excluded in patients with <2 comorbidities and
patients younger than 75 years of age. Other sensitivity
analyses, such as changing price levels of NT-proBNP and
inpatient costs, excluding patients with imputed cost data,
including all 499 patients, and considering those lost or
withdrawn as dead, did not alter the results (Online
Table 4). Cost-effectiveness outcome regarding QALYs
was similar overall to cost-effectiveness outcomes regarding
life-years (Online Table 5).Discussion
Although the TIME-CHF was negative with regard to the
primary endpoint (i.e., hospital-free survival), the secondary
endpoint of HF hospital-free survival was favorably affected by
NT-proBNP-guided therapy and there was a trend toward
improved overall survival (8). Notably, NT-proBNP-guided
therapy significantly improved overall survival and HF-free
survival in the pre-stratified group of patients <75 years of
age but not in those 75 years of age. Other studies using
NT-proBNP guidance in HF patients confirmed this finding
(8,9), but results were not consistent. Thus, it is of particular
Figure 2 Cost-Effectiveness Planes for Life-Years Gained
Joint difference in effectiveness (D life-years, x-axis) and costs (D total costs,
y-axis) from among 1,000 bootstrap samples, representing the uncertainty
surrounding the ICER. The percentage of joint density occupying each quadrant
indicates the likelihood that cost-effectiveness lies in that quadrant. Southeast ¼
more effective and less costly (i.e., dominant); Northeast ¼ more effective and
more costly; Northwest¼ less effective and less costly (i.e., inferior); Southwest¼
less effective and less costly. For SW and NE quadrants, cost-effectiveness
depends on the threshold applied.
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69interest to learn about the cost-effectiveness of NT-proBNP-
guided care, as the fact that no significant differences between
effects were found does not rule out the possibility that an
investigated therapy is good value for the cost (i.e., cost effec-
tive) (5). Whereas the use of NT-proBNP levels was proposed
to be cost effective in other settings, such as the diagnosis and
initial management of patients with dyspnea in the emergency
department (20,21) and screening of asymptomatic left
ventricular dysfunction (22), data for cost-effectiveness of
NT-proBNP-guided outpatient management of HF patientsare limited. One simulation model and 1 relatively small
prospective trial concluded that introduction of NT-proBNP
measurement in chronic HF may be cost effective (10,11).
These studieswere limited by the fact that noor only little actual
cost data were collected. This comprehensive cost-effectiveness
analysis alongside a prospective randomized trial shows that
NT-proBNP-guided therapy has a high chance of being
cost effective in HF patients with reduced LVEF, who are
60years of age.The probability of cost-effectivenesswasmost
pronounced in patients 60 to 74 years of age and in patients
with <2 comorbidities.
Costs directly associated with the intervention (i.e., NT-
proBNP measurements) accounted for <1% of the total
cost, and changing price levels of NT-proBNP measurement
did not alter our results. Results were also robust relative to
changes in price level of inpatient care. The net cost
reduction in our study was caused mainly by a reduction in
residence costs (i.e., staying in a nursing home or home for
the elderly). Whether this is a direct and causative result
of NT-proBNP-guided therapy, however, is difficult to
determine. Factors that might be associated with residency,
like the SF-12 mental and physical component and 6-min
walking distance, did not differ between the treatment
groups, nor did the improvement in these factors over
time (8). Despite randomization, there was some, although
not statistically significant, imbalance between baseline
residency. Because we examined a real-life elderly HF
population for whom residence costs have large socioeco-
nomic consequences (23), it seemed reasonable to include
residence costs in our cost-effectiveness analysis. However,
to avoid overinterpreting the potential benefit of NT-
proBNP-guided therapy in HF, we performed a sensitivity
analysis in which residence costs were excluded. Even in that
scenario, the ICER was still very acceptable ($5,870/life-
year gained), and the chance of NT-proBNP-guided therapy
being cost effective remained 86% at a threshold of $50,000/
life-year gained. In patients 75 years of age and in those
with significant comorbidities, however, the probability of
cost-effectiveness was considerably lowered when residence
costs were excluded, making cost-effectiveness questionable
in these subgroups. In the younger patients and those with
<2 comorbidities, results remained highly in favor of NT-
proBNP-guided therapy.
In comparison with well-established therapies in HF,
NT-proBNP-guided therapy has at least comparable if
not more economic benefits (24). The ICER of NT-
proBNP-guided therapy was well below the range of most
established HF therapies and outpatient strategies, even
after exclusion of residence costs (Online Table 6) (25–30).
As there is no consensus on reasonable threshold value for
cost-effectiveness, thresholds vary widely, up to $100,000
(4,31); we applied an arbitrary threshold of $50,000/life-year
gained (Online Fig. 2 illustrates how readers may apply their
own threshold).
Study strengths and limitations. A particular strength of
our study is that we included a real-life HF population as
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70seen in clinical practice, which is reflected by age and high
number of comorbidities in our population. Also, compre-
hensive costing was performed on a patient level in a
prospective manner.
Several limitations need to be noted. First, cost data and
SF-6D data were not complete for all patients. Therefore, we
imputed missing cost data and SF-6D data by multiple
imputation on an intention-to-treat basis. The influence of
imputed data in sensitivity analysis was negligible. Still, 32
patients were excluded from the life-year analysis, and an
additional 19 were excluded from QALY analysis because
data were too limited for these patients and imputing data
would be based on assumptions only. Excluded patients
differed in many aspects from those included with regard to
baseline characteristics, but a sensitivity analysis including all
499 patients and treating those lost or withdrawn as dead at
last time of contact did not alter our results. Second, our
analyses were not restricted to costs related to HF only.
However, real-life health care costs and responses to inter-
ventions are influenced by comorbidities and expenses cannot
easily be attributed to 1 single disease. To explore this issue,
we performed several subgroup and sensitivity analyses and
showed important influences of comorbidities and residence
costs on our results. Third, our study was underpowered to
perform a test of hypothesis on cost-effectiveness. This is
a very common limitation of health economics evaluations.
To deal with this concern, we report the estimated probability
and display the uncertainty of cost-effectiveness, as appro-
priate (17). As it is likely that cost-effectiveness studies will
become more important regarding the currently overloaded
economic situation, future studies should be more aware of
sample size calculations to be able to draw definite conclu-
sions. Finally, the generalizability of our findings could be
debated as we did not consider differences across countries or
health systems. However, we performed sensitivity analyses
with varying price levels to account for possible uncertainty in
this regard and found that changing price levels did not alter
our results.
Conclusions
NT-proBNP-guided therapy has a high probability of being
cost effective. Importantly, incremental costs of NT-
proBNP measurements themselves were negligible, and
the chance of NT-proBNP-guided therapy increasing costs
without any health benefit is extremely low. Although future
research is required to replicate the study results in a large
trial, our results encourage use of NT-proBNP guidance in
HF care with reduced LVEF, especially in patients <75
years of age and those with <2 comorbidities.
Reprint requests and correspondence: Sandra van Wijk, MD,
Maastricht University Medical Center, Department of Cardiology,
P. Debyelaan 25, PO Box 5800, 6202 AZ Maastricht, the
Netherlands. E-mail: Sandra.van.wijk@mumc.nl.REFERENCES
1. Bundkirchen A, Schwinger RHG. Epidemiology and economic burden
of chronic heart failure. Eur Heart J Suppl 2004;6:D57–60.
2. McMurray JJ, Stewart S. Epidemiology, aetiology, and prognosis of
heart failure. Heart 2000;83:596.
3. Feldman AM, de Lissovoy G, Bristow MR, et al. Cost effectiveness of
cardiac resynchronization therapy in the Comparison of Medical
Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION)
trial. J Am Coll Cardiol 2005;46:2311–21.
4. SandersGD,HlatkyMA,OwensDK.Cost-effectiveness of implantable
cardioverter–defibrillators. N Engl J Med 2005;353:1471–80.
5. Doshi JA, Glick HA, Polsky D. Analyses of cost data in economic
evaluations conducted alongside randomized controlled trials. Value
Health 2006;9:334–40.
6. Felker GM, Hasselblad V, Hernandez AF, O’ Connor CM.
Biomarker-guided therapy in chronic heart failure: a meta-analysis of
randomized controlled trials. Am Heart J 2009;158:422–30.
7. Porapakkham P, Zimmet H, Billah B, Krum H. B-type natriuretic
peptide-guided heart failure therapy: a meta-analysis. Arch Int Med
2010;170:507–14.
8. Pfisterer M, Buser P, Rickli H, et al. BNP-guided vs symptom-guided
heart failure therapy: the Trial of Intensified vs Standard Medical
Therapy in Elderly Patients With Congestive Heart Failure (TIME-
CHF) randomized trial. JAMA 2009;301:383–92.
9. Lainchbury JG, Troughton RW, Strangman KM, et al. N-terminal
pro-B-type natriuretic peptide-guided treatment for chronic heart
failure: results from the BATTLESCARRED (NT-proBNP-assisted
treatment to lessen serial cardiac readmissions and death) trial. J Am
Coll Cardiol 2009;55:53–60.
10. Adlbrecht C, Huelsmann M, Berger R, et al. Cost analysis and
cost effectiveness of NT proBNP guided heart failure specialist
care in addition to home based nurse care. Eur J Clin Invest 2011;
41:315–22.
11. Morimoto T, Hayashino Y, Shimbo T, Izumi T, Fukui T. Is B-type
natriuretic peptide-guided heart failure management cost-effective? Int
J Cardiol 2004;96:177–81.
12. Brunner-La Rocca HP, Buser PT, Schindler R, Bernheim A,
Rickenbacher P, Pfisterer M. Management of elderly patients with
congestive heart failure–design of the Trial of Intensified versus stan-
dard Medical therapy in Elderly patients with Congestive Heart Failure
(TIME-CHF). Am Heart J 2006;151:949–55.
13. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis
and treatment of chronic heart failure: executive summary (update
2005): the Task Force for the Diagnosis and Treatment of Chronic
Heart Failure of the European Society of Cardiology. Eur Heart J 2005;
26:1115–40.
14. Brazier J, Roberts J, Deverill M. The estimation of a preference-based
measure of health from the SF-36. J Health Econ 2002;21:271–92.
15. TARMED Suisse. Bern, Switzerland. [Website]. Available at: http://
www.tarmedsuisse.ch. Accessed November 21, 2012.
16. Medicines Compendium of Switzerland. Available at: http://www.
kompendium.ch. Accessed December 2012.
17. Briggs AH, O’ Brien BJ, Blackhouse G. Thinking outside the box:
recent advances in the analysis and presentation of uncertainty in cost-
effectiveness studies. Ann Rev Public Health 2002;23:377–401.
18. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost effectiveness
analysis up by its bootstraps: a non parametric approach to confidence
interval estimation. Health Econ 1997;6:327–40.
19. Severens JL, Brunenberg DEM, Fenwick EAL, OBrien B, Joore MA.
Cost-effectiveness acceptability curves and a reluctance to lose. Phar-
macoeconomics 2005;23:1207–14.
20. Mueller C, Laule-Kilian K, Schindler C, et al. Cost-effectiveness of
B-type natriuretic peptide testing in patients with acute dyspnea. Arch
Intern Med 2006;166:1081–7.
21. Siebert U, Januzzi JL Jr., Beinfeld MT, Cameron R, Gazelle GS.
Cost-effectiveness of using N-terminal pro-brain natriuretic peptide
to guide the diagnostic assessment and management of dyspneic
patients in the emergency department. Am J Cardiol 2006;98:
800–5.
22. Heidenreich PA, Gubens MA, Fonarow GC, Konstam MA,
Stevenson LW, Shekelle PG. Cost-effectiveness of screening with B-
type natriuretic peptide to identify patients with reduced left ventricular
ejection fraction. J Am Coll Cardiol 2004;43:1019–26.
JACC: Heart Failure Vol. 1, No. 1, 2013 Sanders-van Wijk et al.
February 2013:64–71 Cost-Effectiveness of NT-ProBNP Guidance in HF
7123. Liao L, Allen LA, Whellan DJ. Economic burden of heart failure in
the elderly. Pharmacoeconomics 2008;26:447–62.
24. Weintraub WS, Cole J, Tooley JF. Cost and cost-effectiveness studies
in heart failure research. Am Heart J 2002;143:565–76.
25. Reed SD, Whellan DJ, Li Y, et al. Economic evaluation of the HF-
ACTION (heart failure: a controlled trial investigating outcomes of
exercise training) randomized controlled trial: an exercise training study
of patients with chronic heart failure. Circ Cardiovasc Qual Outcomes
2010;3:374–81.
26. Smith B, Hughes-Cromwick PF, Forkner E, Galbreath AD. Cost-
effectiveness of telephonic disease management in heart failure. Am J
Manag Care 2008;14:106–15.
27. Hebert PL, Sisk JE, Wang JJ, et al. Cost-effectiveness of nurse-led
disease management for heart failure in an ethnically diverse urban
community. Ann Intern Med 2008;149:540–8.
28. Chan DC, Heidenreich PA, Weinstein MC, Fonarow GC. Heart
failure disease management programs: a cost-effectiveness analysis. Am
Heart J 2008;155:332–8.29. Miller G, Randolph S, Forkner E, Smith B, Galbreath AD. Long-term
cost-effectiveness of disease management in systolic heart failure. Med
Decis Making 2009;29:325–33.
30. Turner DA, Paul S, Stone MA, Juarez-Garcia A, Squire I, Khunti K.
Cost-effectiveness of a disease management programme for secondary
prevention of coronary heart disease and heart failure in primary care.
Heart 2008;94:1601–6.
31. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold
and what other factors influence its decisions? A binary choice analysis.
Health Econ 2004;13:437–52.
Key Words: cost effectiveness - heart failure - NT-proBNP.
APPENDIX
For expanded Methods and Results sections and supplemental figures
and table, please see the online version of this article.
